One week after discontinuing Wegovy 2.4 mg injection, start Wegovy 25 mg tablets orally once a day
doi: 10.1007/s11357-021-00469-0
1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87
*Correspondence: Tina Vilsbll [email protected] This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The total distributions over the past 12 months were $3.63, which equates to a yield of about 4%